Department of Nuclear Medicine, Multimodal Neuroimaging Group, University of Cologne, University Hospital of Cologne, Cologne, Germany.
Department of Nuclear Medicine, Multimodal Neuroimaging Group, University of Cologne, University Hospital of Cologne, Cologne, Germany; Research Center Juelich, Institute for Neuroscience and Medicine II, Molecular Organization of the Brain, Juelich, Germany.
Neurobiol Aging. 2021 Oct;106:119-129. doi: 10.1016/j.neurobiolaging.2021.06.014. Epub 2021 Jun 21.
Although beta-amyloid (Aβ) positivity has shown to be associated with higher risk of progression to Alzheimer's disease (AD) in mild cognitive impairment (MCI), information on the time to conversion to manifest dementia cannot be readily deduced from this binary classification. Here, we assessed if regional patterns of Aβ deposition measured with F-florbetapir may serve as biomarker for progression risk in Aβ-positive cognitively normal (CN) and MCI patients, including clinical follow-up data and cerebrospinal fluid (CSF) biomarkers. Voxel-wise group comparisons between age and sex-matched Aβ-positive groups (i.e., CN-stables [n = 38] vs. CN-to-MCI/AD progressors [n = 38], MCI-stables [n = 104] versus MCI-to-AD progressors [n = 104]) revealed higher Aβ burden in precuneus, subcortical, and parietal regions in CN-to-MCI/AD progressors and cingulate, temporal, and frontal regions in MCI-to-AD progressors. Importantly, these regional patterns predicted progression to advanced stages on the AD spectrum in the short and the long-term beyond global Aβ burden and CSF biomarkers. These results suggest that distinct regional patterns of Aβ burden are a valuable biomarker for risk of disease progression in CN and MCI.
虽然β-淀粉样蛋白（Aβ）阳性已被证明与轻度认知障碍（MCI）向阿尔茨海默病（AD）进展的风险增加相关，但从这种二元分类中无法轻易推断出向显性痴呆转化的时间。在这里，我们评估了使用 F-氟比他滨测量的 Aβ沉积的区域模式是否可以作为 Aβ 阳性认知正常（CN）和 MCI 患者进展风险的生物标志物，包括临床随访数据和脑脊液（CSF）生物标志物。在年龄和性别匹配的 Aβ 阳性组（即 CN 稳定组[ n = 38]与 CN 至 MCI/AD 进展组[ n = 38]、MCI 稳定组[ n = 104]与 MCI 至 AD 进展组[ n = 104]）之间，通过体素进行组间比较，发现 CN 至 MCI/AD 进展组的后扣带回、皮质下和顶叶区域以及 MCI 至 AD 进展组的扣带回、颞叶和额叶区域的 Aβ 负担更高。重要的是，这些区域模式在短期内和长期内，除了全局 Aβ 负担和 CSF 生物标志物外，还可以预测 AD 谱中晚期阶段的进展。这些结果表明，Aβ 负担的不同区域模式是 CN 和 MCI 疾病进展风险的有价值的生物标志物。
